Kevin M. Kalinsky
Distinguished in Triple-Negative Breast Cancer

Dr. Kevin M. Kalinsky

Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Triple-Negative Breast Cancer
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Kalinsky is an Oncologist in Atlanta, Georgia. Dr. Kalinsky is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, HER2 Negative Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer.

His clinical research consists of co-authoring 178 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Triple-Negative Breast Cancer.

Specialties
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Recruiting
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drugs: Anastrozole, Palbociclib, Trastuzumab, Pertuzumab
Study Phase: Phase 1/Phase 2
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
Enrollment Status: Terminated
Publish Date: May 18, 2025
Intervention Type: Drug, Biological
Study Drugs: Spartalizumab, LAG525, NIR178, Capmatinib, MCS110, Canakinumab
Study Phase: Phase 1
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Study Phase: Phase 1
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors.
A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors.
Enrollment Status: Suspended
Publish Date: August 19, 2024
Intervention Type: Drug
Study Drugs: APG-2575, Palbociclib
Study Phase: Phase 1/Phase 2
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial
Enrollment Status: Withdrawn
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1
Pre-Surgical Window of Opportunity Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
Pre-Surgical Window of Opportunity Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
Enrollment Status: Completed
Publish Date: August 30, 2023
Intervention Type: Procedure, Drug
Study Drugs: Metformin, Atorvastatin
Study Phase: Early Phase 1
Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib, Trastuzumab
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: July 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer
A Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer
Enrollment Status: Completed
Publish Date: September 10, 2021
Intervention Type: Drug, Other, Procedure
Study Drugs: Propranolol, Paclitaxel, Nab-Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Premedication, Anti-Nausea Therapy, Pegfilgrastim
Study Phase: Phase 2
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 07, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 21 Less Clinical Trials

178 Total Publications

Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
Journal: JCO oncology practice
Published: June 25, 2025
Similar Doctors
Jane L. Meisel
Distinguished in Triple-Negative Breast Cancer
Dr. Jane L. Meisel
Oncology
Distinguished in Triple-Negative Breast Cancer
Dr. Jane L. Meisel
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Meisel is an Oncologist in Atlanta, Georgia. Dr. Meisel has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, and Ovarian Cancer.

Advanced in Triple-Negative Breast Cancer
Dr. Kevin H. Peacock
Hematology Oncology | Oncology | Hematology
Advanced in Triple-Negative Breast Cancer
Dr. Kevin H. Peacock
Hematology Oncology | Oncology | Hematology

North Atlanta Oncology Services LLC

2098 Teron Trce, Suite 400, 
Dacula, GA 
 (30.6 miles away)
678-722-3940
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Peacock is a Hematologist Oncology specialist and an Oncologist in Dacula, Georgia. Dr. Peacock is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Paget Disease of the Breast, and Breast Cancer. Dr. Peacock is currently accepting new patients.

Advanced in Triple-Negative Breast Cancer
Dr. Jonathan C. Bender
Hematology Oncology | Hematology | Oncology
Advanced in Triple-Negative Breast Cancer
Dr. Jonathan C. Bender
Hematology Oncology | Hematology | Oncology

Piedmont Cancer Institute PC

1267 Hwy 54 W, Suite 4200, 
Fayetteville, GA 
 (31.3 miles away)
678-829-1060
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients
Offers Telehealth

Jonathan Bender is a Hematologist Oncology specialist and a Hematologist in Fayetteville, Georgia. Dr. Bender is rated as a Distinguished provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia. Dr. Bender is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kalinsky's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile